IP Verse

Isoxazoline Parasiticide Formulations And Methods For Treating Blepharitis

Patent No. EP3723739 (titled "Isoxazoline Parasiticide Formulations And Methods For Treating Blepharitis") was filed by Tarsus Pharmaceuticals on Dec 14, 2018. The application was issued on Mar 27, 2024.

Patent Summary

Isoxazoline-based ophthalmic compositions for treating ocular Demodex infestation in humans, specifically targeting blepharitis and rosacea. The compositions contain a potent isoxazoline compound as the active ingredient, formulated in sterile eye drops with a compatible vehicle. The treatment is particularly effective for reducing Demodex mite populations in eyelashes, thereby alleviating symptoms of blepharitis and rosacea.

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GENERICS UKDec 23, 2024ELKINGTON AND FIFE
HOFFMANN EITLEDec 12, 2024HOFFMANN EITLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3723739

TARSUS PHARMACEUTICALS
Application Number
EP18889875A
Filing Date
Dec 14, 2018
Status
Granted And Under Opposition
Feb 23, 2024
Publication Date
Mar 27, 2024
External Links
Slate, Register , Google Patents